Advertisement

Cancer Immunology, Immunotherapy

, Volume 59, Issue 3, pp 355–366 | Cite as

A humanized anti-osteopontin antibody inhibits breast cancer growth and metastasis in vivo

  • Jianxin Dai
  • Bohua Li
  • Jinping Shi
  • Ling Peng
  • Dapeng Zhang
  • Weizhu Qian
  • Sheng Hou
  • Lei Zhao
  • Jie Gao
  • Zhiguo Cao
  • Jian Zhao
  • Hao Wang
  • Yajun GuoEmail author
Original Article

Abstract

Osteopontin (OPN) has been implicated as an important mediator of breast cancer progression and metastasis and has been investigated for use as a potential therapeutic target in the treatment of breast cancer. However, the in vivo antitumor effect of anti-OPN antibodies on breast cancer has not been reported. In this study, a mouse anti-human OPN antibody (1A12) was humanized by complementarity-determining region grafting method based on computer-assisted molecular modeling. A humanized version of 1A12, denoted as hu1A12, was shown to possess affinity comparable to that of its parental antibody. The ability of hu1A12 to inhibit cell migration, adhesion, invasion and colony formation was assessed in a highly metastatic human breast cancer cell line MDA-MB-435S. The results indicated that hu1A12 was effective in inhibiting the cell adhesion, migration, invasion and colony formation of MDA-MB-435S cells in vitro. hu1A12 also showed significant efficacy in suppressing primary tumor growth and spontaneous metastasis in a mouse lung metastasis model of human breast cancer. The specific epitope recognized by hu1A12 was identified to be 212NAPSD216, adjacent to the calcium binding domain of OPN. Our data strongly support that OPN is a potential target for the antibody-based therapies of breast cancer. The humanized anti-OPN antibody hu1A12 may be a promising therapeutic agent for the treatment of human breast cancer.

Keywords

Breast cancer Humanized antibody Immunogenicity Metastasis Osteopontin 

Notes

Acknowledgments

We thank Ms. Yang Yang and Ms. Jing Xu for their technical assistance as well as antibody production facility of National Engineering Research Center for Antibody Medicine for providing the purified control antibodies. This work was supported by National Natural Science Foundation of China, Ministry of Science & Technology of China (973 & 863 program projects), National Key Project for Infectious Disease, National Key New Drug Creation and Manufacturing Program and Shanghai Commission of Science & Technology. This study is also supported by Shanghai Leading Academic Discipline Project.

References

  1. 1.
    Denhardt DT, Guo X (1993) Osteopontin: a protein with diverse functions. FASEB J 7:1475–1482PubMedGoogle Scholar
  2. 2.
    Wai PY, Kuo PC (2004) The role of osteopontin in tumor metastasis. J Surg Res 21:228–241CrossRefGoogle Scholar
  3. 3.
    Rodrigues LR, Teixeira JA, Schmitt FL, Paulsson M, Lindmark-Mänsson H (2007) The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev 16:1087–1097CrossRefPubMedGoogle Scholar
  4. 4.
    Senger DR, Perruzzi CA, Papadopoulos A (1989) Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res 9:1291–1299PubMedGoogle Scholar
  5. 5.
    Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF, Senger DR (1994) Osteopontin expression and distribution in human carcinomas. Am J Pathol 145:610–623PubMedGoogle Scholar
  6. 6.
    Denhardt DT (1996) Oncogene-initiated aberrant signaling engenders the metastatic phenotype: synergistic transcription factor interactions are targets for cancer therapy. Crit Rev Oncogenes 7:261–291Google Scholar
  7. 7.
    Chakraborty G, Jain S, Patil TV, Kundu GC (2008) Down-regulation of osteopontin attenuates breast tumor progression in vivo. J Cell Mol Med. doi: 10.1111/j.1582-4934.2008.00263.x
  8. 8.
    Behrend EI, Craig AM, Wilson SM, Denhardt DT, Chambers AF (1995) Expression of antisense osteopontin RNA in metastatic mouse fibroblasts is associated with reduced malignancy. Ann N Y Acad Sci 760:299–301CrossRefPubMedGoogle Scholar
  9. 9.
    Behrend EI, Craig AM, Wilson SM, Denhardt DT, Chambers AF (1994) Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res 54:832–837PubMedGoogle Scholar
  10. 10.
    Adwan H, Bäuerle T, Najajreh Y, Elazer V, Golomb G, Berger MR (2004) Decreased levels of osteopontin and bone sialoprotein II are correlated with reduced proliferation, colony formation, and migration of GFP-MDA-MB-231 cells. Int J Oncol 24:1235–1244PubMedGoogle Scholar
  11. 11.
    Wai PY, Mi Z, Guo H, Sarraf-Yazdi S, Gao C, Wei J, Marroquin CE, Clary B, Kuo PC (2005) Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis. Carcinogenesis 26:741–751CrossRefPubMedGoogle Scholar
  12. 12.
    Cui R, Takahashi F, Ohashi R, Gu T, Yoshioka M, Nishio K, Ohe Y, Tominaga S, Takagi Y, Sasaki S, Fukuchi Y, Takahashi K (2007) Abrogation of the interaction between osteopontin and alphavbeta3 integrin reduces tumor growth of human lung cancer cells in mice. Lung Cancer 57:302–310CrossRefPubMedGoogle Scholar
  13. 13.
    Allan AL, George R, Vantyghem SA (2006) Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol 169:233–246CrossRefPubMedGoogle Scholar
  14. 14.
    Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2:563–572CrossRefPubMedGoogle Scholar
  15. 15.
    Cole BF, Gelber RD, Gelber S, Coates AS, Goldhirsch A (2001) Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet 358:277–286CrossRefPubMedGoogle Scholar
  16. 16.
    Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R, Taylor C, Wang Y, Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366:2087–2106PubMedGoogle Scholar
  17. 17.
    Singhal H, Bautista DS, Tonkin KS, O’Malley FP, Tuck AB, Chambers AF, Harris JF (1997) Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 3:605–611PubMedGoogle Scholar
  18. 18.
    Tuck AB, O’Malley FP, Singhal H, Harris JF, Tonkin KS, Kerkvliet N, Saad Z, Doig GS, Chambers AF (1998) Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 79:502–508CrossRefPubMedGoogle Scholar
  19. 19.
    Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, Yeatman TJ (2004) Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10:184–190CrossRefPubMedGoogle Scholar
  20. 20.
    Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH, Howitt R, West CR (2002) Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 62:3417–3427PubMedGoogle Scholar
  21. 21.
    Tuck AB, Arsenault DM, O’Malley FP, Hota C, Ling MC, Wilson SM, Chambers AF (1999) Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 18:4237–4246CrossRefPubMedGoogle Scholar
  22. 22.
    Shevde LA, Samant RS, Paik JC, Metge BJ, Chambers AF, Casey G, Frost AR, Welch DR (2006) Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435. Clin Exp Metastasis 23:123–133CrossRefPubMedGoogle Scholar
  23. 23.
    Suzuki M, Mose E, Galloy C, Tarin D (2007) Osteopontin gene expression determines spontaneous metastatic performance of orthotopic human breast cancer xenografts. Am J Pathol 171:682–692CrossRefPubMedGoogle Scholar
  24. 24.
    Bautista DS, Xuan JW, Hota C, Chambers AF, Harris JF (1994) Inhibition of Arg-Gly-Asp (RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin. J Biol Chem 269:23280–23285PubMedGoogle Scholar
  25. 25.
    Li B, Wang H, Dai J, Ji J, Qian W, Zhang D, Hou S, Guo Y (2005) Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions. Immunology 116:487–498PubMedGoogle Scholar
  26. 26.
    Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, Avdalovic NM, Levitt M, Junghans RP, Waldmann TA (1989) A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 86:10029–10033CrossRefPubMedGoogle Scholar
  27. 27.
    Pulito VL, Roberts VA, Adair JR, Rothermel AL, Collins AM, Varga SS, Martocello C, Bodmer M, Jolliffe LK, Zivin RA (1996) Humanization and molecular modeling of the anti-CD4 monoclonal antibody, OKT4A. J Immunol 156:2840–2850PubMedGoogle Scholar
  28. 28.
    Kettleborough CA, Saldanha J, Heath VJ, Morrison CJ, Bendig MM (1991) Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. Protein Eng 4:773–783CrossRefPubMedGoogle Scholar
  29. 29.
    Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Li Y, Robles AI, Chen Y, Ma ZC, Wu ZQ, Ye SL, Liu YK, Tang ZY, Wang XW (2003) Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 9:416–423CrossRefPubMedGoogle Scholar
  30. 30.
    Fan K, Dai J, Wang H, Wei H, Cao Z, Hou S, Qian W, Wang H, Li B, Zhao J, Xu H, Yang C, Guo Y (2008) Treatment of collagen-induced arthritis with an anti-osteopontin monoclonal antibody through promotion of apoptosis of both murine and human activated T cells. Arthritis Rheum 58:2041–2052CrossRefPubMedGoogle Scholar
  31. 31.
    Kabat EA, Wu TT, Reid-Miller M, Perry HM, Gottesman KS (1987) Sequences of proteins of immunological interest, 4th edn. United States Department of Health and Human Services, Washington, DCGoogle Scholar
  32. 32.
    Schroff RW, Foon KA, Beatty SM, Oldham RK, Morgan AC Jr (1985) Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 45:879–885PubMedGoogle Scholar
  33. 33.
    Owens RJ, Young RJ (1994) The genetic engineering of monoclonal antibodies. J Immunol Methods 168:149–165CrossRefPubMedGoogle Scholar
  34. 34.
    Morrison SL, Johnson MJ, Herzenberg LA, Oi VT (1984) Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 81:6851–6855CrossRefPubMedGoogle Scholar
  35. 35.
    Boulianne GL, Hozumi N, Shulman MJ (1984) Production of functional chimaeric mouse/human antibody. Nature 312:643–646CrossRefPubMedGoogle Scholar
  36. 36.
    Jones PT, Dear PH, Foote J, Neuberger MS, Winter G (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321:522–525CrossRefPubMedGoogle Scholar
  37. 37.
    Winter G, Harris WJ (1993) Humanized antibodies. Immunol Today 14:243–246CrossRefPubMedGoogle Scholar
  38. 38.
    Kipriyanov SM, Le Gall F (2004) Generation and production of engineered antibodies. Mol Biotechnol 26:39–60CrossRefPubMedGoogle Scholar
  39. 39.
    Presta LG, Lahr SJ, Shields RL (1993) Humanization of an antibody directed against IgE. J Immunol 151:2623–2632PubMedGoogle Scholar
  40. 40.
    Furger KA, Menon RK, Tuck AB, Bramwell VH, Chambers AF (2001) The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 1:621–632CrossRefPubMedGoogle Scholar
  41. 41.
    Xuan JW, Hota C, Chambers AF (1994) Recombinant GST-human osteopontin fusion protein is functional in RGD-dependent cell adhesion. J Cell Biochem 54:247–255CrossRefPubMedGoogle Scholar
  42. 42.
    Senger DR, Perruzzi CA (1996) Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin. Biochim Biophys Acta 1314:13–24CrossRefPubMedGoogle Scholar
  43. 43.
    Tuck AB, Chambers AF (2001) The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia 6:419–429CrossRefPubMedGoogle Scholar
  44. 44.
    Philip S, Kundu GC (2003) Osteopontin induces nuclear factor κB-mediated promatrix metalloproteinase-2 activation through IκBα/IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. J Biol Chem 278:14487–14497CrossRefPubMedGoogle Scholar
  45. 45.
    Das R, Mahabeleshwar GH, Kundu GC (2003) Osteopontin stimulates cell motility and nuclear factor B-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J Biol Chem 278:28593–28606CrossRefPubMedGoogle Scholar
  46. 46.
    Xu H, Jin XQ, Jing L, Li GS (2006) Effect of sodium fluoride on the expression of Bcl-2 family and osteopontin in rat renal tubular cells. Biol Trace Elem Res 109:55–60CrossRefPubMedGoogle Scholar
  47. 47.
    Hashimoto M, Sun D, Rittling SR, Denhardt DT, Young W (2007) Osteopontin-deficient mice exhibit less inflammation, greater tissue damage, and impaired locomotor recovery from spinal cord injury compared with wild-type controls. J Neurosci 27:3603–3611CrossRefPubMedGoogle Scholar
  48. 48.
    Rangaswami H, Bulbule A, Kundu GC (2006) Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16:79–87CrossRefPubMedGoogle Scholar
  49. 49.
    Hijiya N, Setoguchi M, Matsuura K, Higuchi Y, Akizuki S, Yamamoto S (1994) Cloning and characterization of the human osteopontin gene and its promoter. Biochem J 303:255–262PubMedGoogle Scholar
  50. 50.
    O’Regan A, Berman JS (2000) Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int J Exp Pathol 81:373–390CrossRefPubMedGoogle Scholar
  51. 51.
    Yamamoto N, Nakashima T, Torikai M, Naruse T, Morimoto J, Kon S, Sakai F, Uede T (2007) Successful treatment of collagen-induced arthritis in non-human primates by chimeric anti-osteopontin antibody. Int Immunopharmacol 7:1460–1470CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Jianxin Dai
    • 1
  • Bohua Li
    • 1
    • 2
  • Jinping Shi
    • 1
  • Ling Peng
    • 1
  • Dapeng Zhang
    • 1
    • 2
  • Weizhu Qian
    • 1
    • 2
  • Sheng Hou
    • 1
    • 2
  • Lei Zhao
    • 1
  • Jie Gao
    • 1
  • Zhiguo Cao
    • 1
  • Jian Zhao
    • 1
  • Hao Wang
    • 1
    • 2
  • Yajun Guo
    • 1
    • 2
    Email author
  1. 1.International Joint Cancer Institute and 301 General Hospital Cancer CenterThe Second Military Medical UniversityShanghaiPeople’s Republic of China
  2. 2.National Engineering Research Center for Antibody MedicineShanghaiPeople’s Republic of China

Personalised recommendations